| abstract |
【Task】 To provide a novel pharmaceutical composition comprising cyclosporin A, also known as cyclosporine, as an active agent (hereinafter referred to as cyclosporine). [Solution] A surfactant having a HLB value of at least 10 comprising polyoxyethylene sorbitan fatty acid ester and / or sorbitan fatty acid ester; a hydrophilic phase comprising polyethylene glycol and at least one lower alkanol, Each of the alkanols is less than 12% of the total weight of the composition (excluding hard gelatin capsules); however, this is solved by a hard gelatin capsule that is substantially free of oils other than those described above. [Selection figure] None |